Healthcare Industry News: LUCENTIS
News Release - July 26, 2012
Endocyte Appoints David Meek to Newly Created Position of Chief Commercial OfficerWEST LAFAYETTE, Ind., July 26, 2012 -- (Healthcare Sales & Marketing Network) -- Endocyte, Inc. (ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy, today announced the appointment of David Meek to the newly created position of chief commercial officer. Mr. Meek will be responsible for the development of Endocyte's commercial team and the Company's overall commercial strategy and execution.
"David's extensive, senior, global commercial experience and track record of launch success make him an ideal choice to build our sales and marketing capabilities as we prepare to commercialize our lead cancer drug candidate, vintafolide, and our companion imaging diagnostic, etarfolatide," said Ron Ellis, Endocyte's president and CEO. "David's appointment adds breadth to our already strong management team and represents an important step in the next phase of our development."
Mr. Meek brings more than 20 years of pharmaceutical industry experience, including general management in North America and Europe, and numerous successful launches for oncology and specialty products. He comes to Endocyte after more than seven years at Novartis Pharma AG, where he was most recently the head of northern and central Europe oncology and launched key new oncology products and indications for Novartis. Previously, he served as president and CEO of Novartis Pharmaceuticals Canada, where he oversaw the launch of LUCENTIS(R) and other specialty products, and he also served as the global business franchise head for Novartis' respiratory and dermatology franchise in Basel, Switzerland. Prior to joining Novartis, Mr. Meek was at Johnson & Johnson for 15 years, where he held a variety of senior sales and marketing roles across multiple therapeutic areas, including oncology.
"I'm very excited to join the Endocyte team, where I have been compelled by the company's approach to develop innovative therapies accompanied by companion diagnostics," said Mr. Meek. "I look forward to building commercial capabilities to optimize not only the launch of vintafolide and etarfolatide, but to position the company for the significant potential of the SMDC and companion diagnostic platform."
Endocyte is a biopharmaceutical company developing targeted therapies for the treatment of cancer and inflammatory diseases. Endocyte uses its innovative proprietary technology to create novel SMDCs and companion imaging diagnostics for personalized targeted therapies. The company's SMDCs actively target receptors that are over-expressed on diseased cells, relative to healthy cells. This targeted approach is designed to enable the treatment of patients with highly active drugs at greater doses, delivered more frequently, and over longer periods of time than would be possible with the untargeted drug alone. The companion imaging diagnostics are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from targeted treatment.
For additional information, please visit our website at www.endocyte.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.